Edmond de Rothschild Investment Partners led the Series B fundraiser round of Complix. GMIV, a private equity firm, also participated in the round. Complix, a biopharmaceutical firm that develops transformative therapeutics, is headquartered in Hasselt, Belgium.

The fund, called BioDiscovery 4, is the fourth investment fund dedicated to the biotechnology sector. Complix said that the fund will be utilized in the development of its patented Alphabodies product. The therapeutics is being developed to treat cancer and other autoimmune indications. The BioDiscovery 4 is also funding the company's expansion.

"We were attracted by Alphabodies' unique ability to modulate intracellular protein-protein interactions which offers an unprecedented opportunity to create a new class of proprietary and truly differentiated products," said Gilles Nobecourt, Edmond de Rothschild Investment Partners' Partner.  Nobecourt is set to join the board of directors of Complix as part of the financing.

"We were impressed by the team at Complix, which has created this new scaffold and demonstrated in-vitro its potential to address intractable intra cellular targets," explained Nobecourt.